SymKardia

Overview

Our Mission. We are on a mission to advance and improve how cardiac arrhythmias are treated. While currently approved therapies only target the cardiac tissue, we believe that we can revolutionize arrhythmia treatment and improve patient outcomes through selective cardiac neuromodulation.

Funding and backers

Total raised
$4M
2 rounds on record
Latest round
$4M
Convertible Note · Jan 2025 · 21 mo ago
The money's age
Due for its next round
21 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jun 8 Took on debt financing $4.3M · SEC Form D Jan 10, 2025 Raised a round Convertible Note $4M · SEC Form D 2024 Founded
Funding rounds
RoundDateAmountInvestorsSource
Debt Financing Jun 2026 $4.3M — SEC Form D
Convertible Note Jan 2025 $4M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity SymKardia, Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Anthony CaparsoExecutive Officer, DirectorSEC Form D
Bruce KenKnightExecutive OfficerSEC Form D
Steven GirouardExecutive OfficerSEC Form D
Jonathan PicciniExecutive OfficerSEC Form D
Imad LibbusExecutive OfficerSEC Form D
Dwight SkinnerExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Y Combinator
backs SafeBeat Rx
Soma Capital
backs SafeBeat Rx
b2venture
backs RetinAI
New York Angels
backs StimCardio
Xontogeny
backs CereVasc eShunt® Device | Under Development for Hydrocephalus
TVM Capital Life Science
backs Vektor Medical
Similar startupsby what they do, their industry and backers
StimCardioSeries A $30M · this month · Founded 2025 · 11-50 employees
StimCardio delivers innovative cardiac stimulation solutions designed to improve patient outcomes, support clinicians, and advance the…
Vektor MedicalSeries A $16M · 2 yr ago · Founded 2017 · 51-200 employees
Discover vMap - The FDA-Cleared Non-Invasive AI-based Arrhythmia Analysis Solution by Vektor Medical. Improve Cardiac Ablation Efficiencies…
RetinAI201-500 employees · 6 roles
RetinAI develops solutions to generate and organize insights and knowledge to improve patient outcomes.
CereVasc eShunt® Device | Under Development for HydrocephalusVenture round $11.1M · 6 yr ago · Founded 2020 · 51-200 employees
The CereVasc eShunt® device is intended to improve patient outcomes and redefine the treatment of communicating hydrocephalus.
SafeBeat Rx11-50 employees · 3 roles
Powering Cardiac Therapeutics - All From Your Phone. SafeBeat goes beyond diagnostics to guide cardiac care.
Xtant MedicalVenture round $5M · 2 yr ago · 4 roles
Precision. Performance. Progress. Our innovations empower surgeons and improve patient outcomes while respecting the selfless gift of…

Financials

Total raised
$8.3M
Latest round
Debt Financing
Funding rounds
2
Funding rounds
Round Announced Amount
Debt Financing 2026 $4.3M Details
Convertible Note 2025 $4M Details

People

Anthony Caparso
Executive Officer, Director
SEC Form D
Bruce KenKnight
Executive Officer
SEC Form D
Steven Girouard
Executive Officer
SEC Form D
Jonathan Piccini
Executive Officer
SEC Form D
Imad Libbus
Executive Officer
SEC Form D
Dwight Skinner
Executive Officer
SEC Form D
Robert Picarel
Director
SEC Form D
Arun Sridhar
Director
SEC Form D
Claudio Rumazza
Director
SEC Form D
Alain Garcinuno Collet
Director
SEC Form D
James Blouzard
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Westlake United States
HQ